MAMoe Hein Aung

Moe Hein Aung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Moe Hein Aung has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape

    by Tara Shooshani, Balaji Cherupalla, Amy Durand, Moe Hein Aung

    Thyroid eye disease (TED), the principal extrathyroidal manifestation of Graves’ disease, is an autoimmune orbitopathy. The pathophysiology involves aberrant thyroid-stimulating hormone receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) signaling on orbital fibroblasts, leading to glycosaminoglycan accumulation, adipogenesis, inflammatory edema, and extraocular-muscle enlargement. The active phase is typically self-limited yet medically modifiable, characterized primarily by inflammation, edema, and tissue expansion, whereas chronic inactive disease is dominated by fibrosis and fixed structural change. This US-oriented review aims to provide updates in the field through 2026: (1) summarizing the molecular pathophysiology linking thyroid autoimmunity to orbital remodeling and current drug targets; (2) discussing activity-versus-severity assessment, with appraisal of the Clinical Activity Score (CAS); and (3) explaining the complementary roles of different structural and functional imaging modalities in the evaluation and management of TED. We then follow the therapeutic ladder, from conservative measures through the employment of glucocorticoids and steroid-sparing immunosuppression to the use of targeted biologics. We give particular attention to IGF-1R inhibition, including the use of teprotumumab and veligrotug, and to post-approval results, including otologic and metabolic adverse-event burden, recurrence, treatment sequencing, and the emerging efficacy of the treatment of chronic and low-activity disease. The CAS’s limited inter-observer reliability identifies additional reproducible activity measures as an open need.

  • Open Access

    Early Detection of Glaucoma and Diabetic Retinopathy in Low-Resource Settings: Barriers and Solutions

    by Esha Gupta, Moe Hein Aung, Eileen Bowden

    Diabetic retinopathy (DR) and glaucoma, globally leading causes of irreversible blindness, can be detected and managed early with timely screening. In low-resource settings, access to ophthalmological examination is limited by a variety of constraints, including scarcity of specialists, equipment costs, geographic distance from care centers, and limited patient awareness. This narrative review examines the principal barriers to early detection of glaucoma and DR and evaluates evidence-based strategies to overcome them, including low-cost portable ophthalmic testing tools, artificial intelligence (AI) analytics, risk-based resource allocation, teleophthalmology, and targeted patient education. In different populations, these strategies have been shown to meaningfully increase access to ophthalmologic screening and follow-up at a significantly lower cost. We describe these approaches, demonstrate previously successful initiatives, and propose various combined approaches adapted to the specific needs of the various low-resource settings.

  • Open Access

    Case Reports of Teprotumumab as Treatment for Monoclonal Antibody-Induced Thyroid Orbitopathy

    by Jared Moon, Nicole Duncan, Jeff Yorio, Ethan Meltzer, Moe H. Aung

    Background and Clinical Significance: Targeted biologic therapies, especially monoclonal antibodies (mAbs) such as nivolumab and alemtuzumab, have revolutionized treatment for malignancies and autoimmune conditions but can cause rare immune-related adverse events (IRAEs), including orbitopathy. To date, only a handful of cases have described the treatment of thyroid eye disease secondary to mAbs, and even fewer have described how to treat refractory disease. Case Presentation: We are illustrating two cases in this report: a 73-year-old woman who developed thyroid eye disease (TED) after nivolumab therapy for melanoma, and a 36-year-old man who presented with TED following alemtuzumab treatment for multiple sclerosis. Both patients failed corticosteroid therapy but showed a significant improvement with teprotumumab, an anti-insulin-like growth factor (IGF)-1 receptor mAb. Conclusions: These cases highlight underrecognized orbital IRAEs linked to mAb therapy and demonstrate teprotumumab’s potential as an effective option for steroid-refractory thyroid orbitopathy. Clinicians should maintain an awareness of orbital complications in patients receiving mAbs to enable prompt diagnosis and intervention, minimizing visual morbidity. Further studies are needed to clarify the pathogenesis of mAb-associated orbitopathy and to establish evidence-based treatment protocols for these rare but impactful complications.


  • Open Access

    Stimulus type and duration affect magnitude and evolution of flicker-induced hyperemia measured by laser speckle flowgraphy at the optic disc and peripapillary vessels

    by Moe H. Aung, Tomas S. Aleman, Arielle S. Garcia, Brendan McGeehan, Gui-Shuang Ying, Robert A. Avery

    Neurovascular coupling is a vital mechanism employed by the cerebrovascular system, including the eye, to regulate blood flow in periods of neuronal activation. This study aims to investigate if laser speckle flowgraphy (LSFG) can detect coupling response elicited by flickering light stimuli and how variations in stimulus type and duration can affect the magnitude and evolution of blood flow in the optic nerve head (ONH) and peripapillary vessels. Healthy adults were exposed to two types of 10-Hz flicker stimuli: a photopic negative response-like stimulus (PhNR-S) or a visual evoked potential-like stimulus (VEP-S)—each presented in separate 10- and 60-s epochs. Both PhNR-S and VEP-S significantly increased ONH blood flow (p < 0.001) immediately after flicker cessation, with a trend of 60-s stimuli (PhNR-S = 11.6%; VEP-S = 10.4%) producing a larger response than 10-s stimuli (PhNR-S = 7.5%; VEP-S = 6.2%). Moreover, exposure to 60-s stimuli elicited a significantly prolonged ONH hyperemic response, especially with PhNR-S. Lastly, stimulation with either 60-s stimuli elicited a robust increase in blood flow within the peripapillary arterioles (p < 0.01) and venules (p < 0.01) as well. Flicker stimulation with common visual electrophysiology stimuli (PhNR-S and VEP-S) induced a demonstrable increase in ONH and peripapillary vessel blood flow, which varied with flicker duration. Our results validate that LSFG is a robust method to quantify flicker-induced hyperemic responses and to study neurovascular coupling in humans.


  • A Tale of Progressive Painless Vision Loss in a 64-Year-Old Man Due to Leber Hereditary Optic Neuropathy

    by Moe H. Aung, Nicholas J. Volpe, Daniel J. Choi, Joel M. Stein, Amy Goldstein, Grant T. Liu

    A 64-year-old man presented with painless sequential bilateral vision loss, consistent with optic neuropathy, over the span of months. The significant decline in his visual function was out of proportion to the appearance of the optic nerves (which were not pale) or changes in his retinal nerve fiber layer thickness on optical coherence tomography. Neuroimaging revealed only mild T2 signal abnormality and faint enhancement in the left optic nerve. Extensive workup for potential infectious, metabolic, inflammatory, and ischemic etiologies was unremarkable. Empiric treatment with intravenous steroids did not slow or ameliorate the vision loss. Ultimately, genetic analysis revealed a missense m.11778G>A mutation in mitochondrial MT-ND4 gene, consistent with Leber hereditary optic neuropathy. Initiation of multivitamin supplements and idebenone unfortunately did not result in recovery of vision.